The increased CD155 expression on cancer cells leads to the proteasomal degradation of costimulatory receptor DNAM-1 on cytotoxic T cells, eventually resulting in the dysfunctional activity of CD8+ T cells in both human and mouse tumors [44]. This evidence concerns the gene CD8A and cancer.